In a report released yesterday, Thomas Smith from Leerink Partners initiated coverage with a Buy rating on Connect Biopharma Holdings (CNTB – Research Report) and a price target of $22.00. The company's shares closed last Friday at $3.05, close to its 52-week low of $2.34. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.6% and a 28.0% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings with a $22.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-connect-biopharma-holdings-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Connect Biopharma Charts.
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Connect Biopharma Charts.